Microplastics in the Air: Global Study Uncovers Concerning Levels of Daily Exposure
30.9.2025 03:00:00 CEST | Business Wire | Press Release
The PlasticDustCloud project, a global study led by the Eurofins Environment Testing network, has revealed alarming microplastic pollution in air, with deposition rates of up to 1,300 microplastics per square metre per day (/m2/day). Working with samples collected across 12 sites in 9 countries on 3 continents, this global study highlights the pervasive presence of microplastics in the air we breathe every day.
Microplastics, defined as particles smaller than 5 mm, are now ubiquitous in the environment. Recent toxicological studies show that microplastics pose potential risks to human health and the environment, raising growing global concerns.
Research, results and methodology
In mid-2024, samples were collected using a harmonised deposition methodology at urban sites in Melbourne (AU), Budapest (HU), Bergen (NO), Gijón (ES), Rovaniemi (FI), Aabybro (DK), Barneveld (NL), Northampton (UK), Sacramento and South Bend (USA). Rural sites in Pelkosenniemi (FI) and Alta (NO) provided reference samples for comparison.
Samples were prepared and analysed across all Eurofins Environment Testing laboratories that perform microplastic testing using a suite of state-of-the-art detection technologies, including spectroscopical (FTIR, LDIR, Raman) and thermoanalytical(Pyrolysis-GC/MS, TED-GC/MS) technologies. Stringent QA/QC protocols were applied throughout the process.
The results showed deposition rates varying by site and detection method, ranging from 1,250 particles/m2/day in Barneveld (NL) and up to 3,110 μg/m2/day in Bergen (NO) using spectroscopy and thermoanalytical technologies respectively. Polyethylene and polypropylene were the most common polymers, reflecting global plastic production trends. Tyre wear particles measured up to 304 μg/m²/day, indicating road traffic as a significant contributor to environmental microplastic prevalence. Most particles detected were smaller than 100 μm that is within the breathable fraction. Significant differences were observed even between adjacent sampling points and using the same testing method, emphasising the heterogeneous distribution of airborne microplastics. These findings contribute critical data, demonstrating that microplastic pollution affects air quality globally and underscoring the need for coordinated international action. The full report is available at: plasticdustcloud.com
About the Eurofins Environment Testing network
The Eurofins Environment Testing network of laboratories contributes to a clean and safe environment by providing market-leading laboratory testing, monitoring and consulting services to a wide range of industrial companies, environmental consultants, contractors, retailers and government authorities.
Please visit: https://www.eurofins.com/environment-testing/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250929140266/en/
Contacts
For further information contact:
Julia Jaeger
Technical Specialist
Australia
Julia.Jaeger@eurofinsanz.com
Gábor Bordós
Business Unit Manager
Hungary
Gabor.Bordos@etcee.eurofins.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press Release
Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings, assigned on 12 June 2026. Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation of the company’s
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press Release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magic Quadrant confirms the shift has moved from pilot to boardroom priority. According to Gartner, Visionaries "understands where the market
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press Release
Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The valve features the company’s FREE next generation tissue treatment addressing the two main causes of calcification, phospholipids and aldehydes. Its proprietary LANCELOT advanced manufacturing process includes zero-pressure shaping and laser cutting of
Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale9.10.2026 15:00:00 CEST | Press Release
Ada, the pioneer in Agentic Customer Experience, today announced it has achieved the Amazon Web Services (AWS) Travel and Hospitality Competency. The designation recognizes Ada as an AWS Partner with demonstrated technical proficiency and proven customer success helping travel and hospitality brands resolve customer issues at scale. Ada joins a select group of 58 AWS Partners holding the competency, and it reflects a shared commitment to helping travel brands deliver service that holds up on their busiest, most unpredictable days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009673638/en/ Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale "Travel is where agentic customer service gets tested hardest. Demand spikes without warning, policies change by the hour, and customers are often stressed and far from home," said Mike Murchison, CEO and co-founder of Ada. "Our airline and hospitali
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom